Compare Southwest Airlines Co (LUV) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs Organon & Co. Common Stock — how do they compare? Southwest Airlines Co trades at $39.3 (market cap $19.89B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Southwest Airlines Co is far larger — about 5.5× Organon & Co. Common Stock's market cap, and Southwest Airlines Co pays the higher dividend (1.77%). Which is the better fit depends on your goals — on Pluang, investors hold Southwest Airlines Co for 66 Days and Organon & Co. Common Stock for 0 Days on average.
| LUV | OGN | |
|---|---|---|
Market Cap | $19.89B | $3.62B |
Volume | 3,985,163 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $54.80 | $13.81 |
52-Week Low | $29.67 | $5.70 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $22.98B | $11.04B |
Dividend Yield | 1.77% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $39.34, down 3.48% today, showing bearish technical signals with mixed earnings performance. The company reported a Q2 2026 EPS beat ($0.94 vs $0.51 expected) but missed Q1 expectations. Fundamentals show modest revenue growth to $28.06B in 2025 with a thin 2.78% net margin, though valuation appears reasonable with P/S of 0.71 and P/E of 25.41. Recent news highlights Southwest's commercial transformation initiatives targeting over $2B EBIT in 2026.
LUV presents a turnaround opportunity with analyst consensus target of $49.61 offering 26% upside, though near-term headwinds from high fuel costs and competitive pressures persist. The stock's bearish technical setup and volatile earnings history require careful risk management, but successful execution of revenue initiatives could drive significant shareholder value.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
